|
17 Dec 2020 |
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
|
|
16 Dec 2020 |
Arecor Limited: First Patient Dosed in Phase I Clinical Trial of Ultra-Concentrated Rapid Acting Insulin Candidate, AT278, for Diabetes
|
|
16 Dec 2020 |
Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
|
|
16 Dec 2020 |
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
|
|
11 Dec 2020 |
Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
|
|
10 Dec 2020 |
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
|
|
09 Dec 2020 |
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
|
|
08 Dec 2020 |
Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH
|
|
08 Dec 2020 |
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
|
|
07 Dec 2020 |
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
|
|
06 Dec 2020 |
Bioniz Announces Positive Clinical Data of BNZ-1, First Anti-Cytokine Therapy to Demonstrate Efficacy in Treating Refractory Cutaneous T-Cell Lymphoma
|
|
06 Dec 2020 |
FDA approves Saxenda® for the treatment of obesity in adolescents aged 12–17
|
|
04 Dec 2020 |
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
|
|
04 Dec 2020 |
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
|
|
02 Dec 2020 |
Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
|
|
28 Nov 2020 |
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
|
|
23 Nov 2020 |
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
|
|
23 Nov 2020 |
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin® Therapeutic Candidate MP0420
|
|
18 Nov 2020 |
FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
|
|
17 Nov 2020 |
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
|
|
17 Nov 2020 |
Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial
|
|
17 Nov 2020 |
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
|
|
16 Nov 2020 |
Genenta’s Temferon™: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme
|
|
16 Nov 2020 |
Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH
|
|
15 Nov 2020 |
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
|
